Literature DB >> 30167765

Validation and cultural adaptation of the qualisex questionnaire in patients with axial spondyloarthritis in Argentina.

Fernando Andres Sommerfleck1, Emilce Edith Schneeberger2, Maria Celeste Orozco2, Natalia Zamora2, Margarita Landi2, Gustavo Citera2.   

Abstract

The Qualisex questionnaire was developed and validated to assess sexuality in patients with rheumatoid arthritis. To the best of our knowledge, there is no instrument to evaluate sexuality in axial spondyloarthritis (axSpA). For this reason, the objective of this study was to validate and adapt the Qualisex questionnaire in axSpA and evaluate the impact of the disease on patients' sexuality. Cross sectional study. Consecutive patients, with ≥ 21 years of age, diagnosed with axSpA according to ASAS'09 criteria were included. Sexual health was assessed using the Qualisex questionnaire. The original version was translated to Spanish and adapted to axSpA. Internal consistency, and test re-test reliability was calculated. Criterion and construct validity were assessed by comparing the Qualisex with parameters of disease activity functional capacity and quality of life. 61 patients were invited to participate in the study, 11 of whom refused. 50 patients were included; 40 (80%) were males, with a median age of 47 years (IQR 21-72) and a median disease duration of 13 years (IQR 1-46). Reproducibility was excellent with an ICC of 0.99 (95% CI 0.65-1). The Qualisex had a good correlation with different disease evaluation parameters. The Qualisex was significantly higher among women (5.4 in women vs. 2.5 in men, p = 0.02), unemployed (4.7 in unemployed vs. 2.3 in employed, p = 0.01), in patients with higher disease activity (4.2 in active patients vs. 1.6 in inactive patients, p = 0.01), and it was lower in patients receiving biologic therapy (BT) (1.9 with BT vs. 3.8 without BT, p = 0.01). Multivariable analysis showed that female sex, longer disease duration and higher disease activity were independently associated with a greater impact on sexuality. The Qualisex adapted to axSpA is a valid and reliable questionnaire. Female axSpA patients, those with longer disease duration and higher disease activity presented a worse sexual life.

Entities:  

Keywords:  Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis; Qualisex; Sexuality

Mesh:

Substances:

Year:  2018        PMID: 30167765     DOI: 10.1007/s00296-018-4148-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  29 in total

1.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.

Authors:  L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

2.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

3.  A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis.

Authors:  Fernando A Sommerfleck; Emilce E Schneeberger; Emilio E Buschiazzo; José A Maldonado Cocco; Gustavo Citera
Journal:  Clin Rheumatol       Date:  2012-08-16       Impact factor: 2.980

Review 4.  Sexual dysfunction in patients with psoriasis and psoriatic arthritis--a systematic review.

Authors:  Patricia Shu Kurizky; Licia Maria Henrique da Mota
Journal:  Rev Bras Reumatol       Date:  2012-12

5.  Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.

Authors:  Walter P Maksymowych; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Désirée van der Heijde
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

6.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

7.  Stress-vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis.

Authors:  Andrea W M Evers; Floris W Kraaimaat; Rinie Geenen; Johannes W G Jacobs; Johannes W J Bijlsma
Journal:  J Psychosom Res       Date:  2003-10       Impact factor: 3.006

8.  Health care utilization in patients with spondyloarthropathies.

Authors:  J A Singh; V Strand
Journal:  Rheumatology (Oxford)       Date:  2009-01-16       Impact factor: 7.580

9.  Impact of ankylosing spondylitis on sexual function: A systematic review and meta-analysis.

Authors:  Ya-Fei Liu; Hui Dong; Zhe Chen; Y U Wang; Sheng-Hao Tu
Journal:  Exp Ther Med       Date:  2015-01-29       Impact factor: 2.447

10.  Rheumatoid arthritis and sexuality: a patient survey in France.

Authors:  Gisela Kobelt; Brigitte Texier-Richard; Sylvain Mimoun; Anne-Sophie Woronoff; David-Romain Bertholon; Aleth Perdriger; Yves Maugars; Bernard Combe
Journal:  BMC Musculoskelet Disord       Date:  2012-09-10       Impact factor: 2.362

View more
  3 in total

Review 1.  Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis.

Authors:  Gustavo Citera; Wilson Bautista-Molano; Ingris Peláez-Ballestas; Valderilio F Azevedo; Risto A Perich; José A Méndez-Rodríguez; Mariel S Cutri; Cecilia E Borlenghi
Journal:  Adv Rheumatol       Date:  2021-01-08

2.  Are Austrian practitioners ready to use medical apps? Results of a validation study.

Authors:  Fanni Hofer; Daniela Haluza
Journal:  BMC Med Inform Decis Mak       Date:  2019-04-24       Impact factor: 2.796

3.  Readiness to use telemonitoring in diabetes care: a cross-sectional study among Austrian practitioners.

Authors:  Domenik Muigg; Peter Kastner; Georg Duftschmid; Robert Modre-Osprian; Daniela Haluza
Journal:  BMC Med Inform Decis Mak       Date:  2019-01-29       Impact factor: 2.796

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.